Skip to content

Comparison of the efficacy, tolerance and cost of Algostéril vs Negative Pressure Therapy in preparation for skin grafting following surgical excision

Comparison of the efficacy, tolerance and cost of Algostéril vs Negative Pressure Therapy in preparation for skin grafting following surgical excision: a multicentre prospective randomised parallel group trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN60292377
Enrollment
112
Registered
2015-02-23
Start date
2014-07-02
Completion date
Unknown
Last updated
2023-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical removal with a granulation phase before a skin graft supported in restorative, reconstructive and plastic surgery service Surgery Skin graft

Interventions

Surgical excision of the skin and underlying tissues are carried out in plastic surgery for tumor traumatic or infectious causes. If the resulting defect is well vascularized, it can be covered by a t

Sponsors

Laboratoires Brothier
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Written informed consent 2. Patients aged 18 years or older 3. Scheduled for surgical removal with a granulation phase before a skin graft

Exclusion criteria

Exclusion criteria: 1. Uncontrolled hyperglycemia 2. Excision is secondary to burns 3. Treated within 30 days before enrollment with immunosuppressants, chemotherapy, radiotherapy on the site excised,

Design outcomes

Primary

MeasureTime frame
Time to optimal granulation. After excision, evaluation for grafting every 7 days and until the wound can receive skin graft.

Secondary

MeasureTime frame
1. Care costs: at each dressing change 2. Patient quality of life: every 7 days and until the wound can receive skin graft. 3. Tolerance: thought the trial

Countries

France

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026